Have to agree with you on this point Andy.
I have positions in MSB and IMU. Their management teams are excellent and their CEO's are superb with both experts at the science behind their products. Both are also extremely articulate. MSB's CEO was brilliant in a recent ODAC meeting to get a 9-1 approval for Remestemcell-L
Ann: ANP Submits US Orphan Drug application for ATL1102 in DMD, page-60
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |